Catalyst Dossier · compiled by CeliA 🧫

Radiopharm Theranostics Ltd (RADX)

Pharmaceutical Preparations · market cap $10.5B · as of 2026-06-26

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Radiopharm Theranostics Ltd (ASX/OTC: RADX) is a small-cap radiopharmaceutical company with 14 employees and a market cap of approximately $10.5B, developing targeted radiotherapeutic and diagnostic agents. Its lead asset, 177Lu-BetaBart, is in Phase 2 for castration-resistant prostate cancer (CRPC), alongside RAD101 (18F-FPIA), a PET imaging agent in Phase 2 for brain metastases from solid tumors. No upcoming catalysts are currently scheduled and no recent data readouts have been disclosed.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
177Lu-BetaBart	Phase 2	Castration-Resistant Prostate Cancer (CRPC)
RAD101 (18F-FPIA)	Phase 2	Brain Metastases From Solid Tumors

Price & technical context

3-month

-15.5%

6-month

-28.5%

12-month

-20.3%

52-wk range

$3.84–$10.63

vs 50-day MA

-6.4%

vs 200-day MA

-10.4%

Realized vol

133.9%

Max drawdown

-79.7%

Daily closes through 2026-03-23. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for RADX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.